Utilization of proton therapy: Evidence-based, market-driven, or something in-between?

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 36, Issue 2, 2013, Pages 192-196

  Dvorak, Tomas ^a,b,d   Fitzek, Markus M ^c   Wazer, David E ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d M D ANDERSON CANCER CENTER ORLANDO   (United States)

Author keywords

cost; proton therapy; utilization

Indexed keywords

ADULT; ARTICLE; CANCER RADIOTHERAPY; EVIDENCE BASED PRACTICE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MARKETING; ONCOLOGY; PATIENT ASSESSMENT; PROTON THERAPY; RADIATION DOSE FRACTIONATION; SENSITIVITY ANALYSIS; TREATMENT DURATION;

EVIDENCE-BASED MEDICINE; HEALTH CARE COSTS; HUMANS; MEDICARE; NEOPLASMS; PROTON THERAPY; RADIATION ONCOLOGY; UNITED STATES;

EID: 84876123203     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3182438d92     Document Type: Article

References (23)

1. Suit H, Kooy H, Trofimov A, et al. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No. Radiother Oncol. 2008;86:148-153.
2. Brada M, Pijls-Johannesma M, De Ruysscher D. Proton therapy in clinical practice: current clinical evidence. J Clin Oncol. 2007; 25:965-970.
3. Lodge M, Pijls-Johannesma M, Stirk L, et al. A systematic literature review of the clinical and cost-effectiveness of hadron therapy in cancer. Radiother Oncol. 2007;83:110-122.
4. Terasawa T, Dvorak T, Ip S, et al. Systematic review: charged-particle radiation therapy for cancer. Ann Intern Med. 2009; 151:556.
5. Peeters A, Grutters JP, Pijls-Johannesma M, et al. How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons. Radiother Oncol. 2010;95: 45-53.
6. Lundkvist J, Ekman M, Ericsson SR, et al. Proton therapy of cancer: potential clinical advantages and cost-effectiveness. Acta Oncol. 2005;44:850-861.
7. Konski A, Speier W, Hanlon A. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? J Clin Oncol. 2007;25:3603-3608.
8. Pijls-Johannesma M, Pommier P, Lievens Y. Cost-effectiveness of particle therapy: current evidence and future needs. Radiother Oncol. 2008;89:127-134.
9. Grutters JP, Pijls-Johannesma M, Ruysscher DD, et al. The cost-effectiveness of particle therapy in non-small cell lung cancer: exploring decision uncertainty and areas for future research. Cancer Treat Rev. 2010;36:468-476.
10. Goozner M. The proton beam debate: are facilities outstripping the evidence? J Natl Cancer Inst. 2010;102:450-453.
11. Mell LK, Mehrotra AK, Mundt AJ. Intensity-modulated radiation therapy use in the U.S., 2004. Cancer. 2005;104:1296-1303.
12. Dvorak T, Wazer DE. Evaluation of potential proton therapy utilization in a market-based environment. J Am Coll Radiol. 2010;7:522-528.
13. DeLaney TF, Kooy HM. Proton and Charged Particle Radiotherapy. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
14. Radiation Oncology wikibook textbook. Available at: http://en.wikibooks. org/wiki/Radiation-Oncology/Protons. Accessed May 30, 2010.
15. Zietman AL. The Titanic and the iceberg: prostate proton therapy and health care economics. J Clin Oncol. 2007;25:3565-3566.
16. Baron MH, Pommier P, Favrel V, et al. A "one-day survey": as a reliable estimation of the potential recruitment for proton-and carbon-ion therapy in France. Radiother Oncol. 2004;73(suppl 2): S15-S17.
17. Mayer R, Mock U, Jäger R, et al. Epidemiological aspects of hadron therapy: a prospective nationwide study of the Austrian project MedAustron and the Austrian Society of Radiooncology (OEGRO). Radiother Oncol. 2004;73(suppl 2):S24-S28.
18. Krengli M, Orecchia R. Medical aspects of the National Centre For Oncological Hadrontherapy (CNAO-Centro Nazionale Adro-terapia Oncologica) in Italy. Radiother Oncol. 2004;73(suppl 2): S21-S23.
19. Glimelius B, Ask A, Bjelkengren G, et al. Number of patients potentially eligible for proton therapy. Acta Oncol. 2005;44: 836-849.
20. Owen JB, Coia LR. The changing structure of radiation oncology: implications for the era of managed care. Semin Radiat Oncol. 1997;7:108-113.
21. Tubiana M. Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review. Radiother Oncol. 2009;91:4-15; discussion 1-3.
22. Arcangeli G, Saracino B, Gomellini S, et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2010;78:11-18.
23. Katz AJ, Santoro M, Ashley R, et al. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol. 2010;10:1.